KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Deferred Revenue (2016 - 2022)

Bio-Rad Laboratories has reported Current Deferred Revenue over the past 13 years, most recently at $52.2 million for Q4 2022.

  • Quarterly Current Deferred Revenue fell 26.48% to $52.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $52.2 million through Dec 2022, down 26.48% year-over-year, with the annual reading at $52.2 million for FY2022, 26.48% down from the prior year.
  • Current Deferred Revenue was $52.2 million for Q4 2022 at Bio-Rad Laboratories, down from $71.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $71.0 million in Q4 2021 and troughed at $26.9 million in Q4 2018.
  • The 5-year median for Current Deferred Revenue is $42.5 million (2020), against an average of $44.5 million.
  • Year-over-year, Current Deferred Revenue surged 67.06% in 2021 and then decreased 26.48% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $26.9 million in 2018, then grew by 25.24% to $33.7 million in 2019, then increased by 25.98% to $42.5 million in 2020, then surged by 67.06% to $71.0 million in 2021, then decreased by 26.48% to $52.2 million in 2022.
  • Per Business Quant, the three most recent readings for BIO's Current Deferred Revenue are $52.2 million (Q4 2022), $71.0 million (Q4 2021), and $42.5 million (Q4 2020).